Administering Bifidobacterium pseudolongum With Arsenic Trioxide Attenuates Acute Promyelocytic Leukemia in Mice by Restoring Immune Microenvironment and Intestinal Homeostasis
Frontiers in Bioscience-Landmark · 2026
DOI: 10.31083/fbl48584 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2026. Verfasst von Zhibo Guo und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, 150001 Harbin, Heilongjiang, China. Hauptthemen laut MEDLINE: Arsenic Trioxide, Leukemia, Promyelocytic, Acute, Bifidobacterium, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Heilongjiang Key R&D Program, Fundamental Research Funds for the Provincial Universities in Heilongjiang Province (2025).
Abstract (Originalsprache)
Objective
Arsenic trioxide (ATO) is a cornerstone of acute promyelocytic leukemia (APL) therapy but induces severe gut microbiota dysbiosis, limiting its efficacy and safety. This study investigated whether adjunctive Bifidobacterium pseudolongum (BP) could mitigate these adverse effects and enhance therapeutic outcomes.
Methods
16S rRNA gene sequencing data of gut microbiota were obtained from a cohort of 22 APL patients treated with ATO-based regimens (20 of 22 data were obtained and analysis further), accessible under BioProject ID PRJNA935705. To evaluate the within-sample microbial community richness and evenness, alpha and beta diversity indices were calculated. Using a murine APL model, we compared ATO monotherapy with ATO+BP co-treatment. Analyses included fecal metagenomic sequencing, single-cell RNA sequencing (sc-RNA-seq), flow cytometric immune profiling, and assessment of intestinal tight junction proteins (claudin-1, occludin, and ZO-1) via immunofluorescence.
Results
ATO treatment significantly reduced gut microbial diversity and depleted beneficial taxa. Sc-RNA-seq data showed that ATO could orchestrate the APL immune microenvironment mainly through functional activation of CD8+ T cells and monocytes. BP supplementation restored microbial homeostasis and synergistically enhanced ATO’s antileukemic effect, reducing the leukemic burden in peripheral blood by 72% and in bone marrow by 64% compared to ATO alone. Mechanistically, BP preserved intestinal barrier integrity by upregulating tight junction protein expression and modulated anti-tumor immunity, notably increasing bone marrow CD8+ T cells by 2.21-fold.
Conclusions
BP is an effective adjunct to ATO therapy, counteracting gut dysbiosis, intestinal damage, and the immune microenvironment while synergistically improving antileukemic efficacy. Targeting the gut–leukemia axis with BP represents a promising strategy for improving the precision and safety of APL treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, First Affiliated Hospital of Harbin Medical University, 150001 Harbin, Heilongjiang, China.
- Department of Hematology, First Affiliated Hospital of Harbin Medical University, 150001 Harbin, Heilongjiang, China.
- NHC Key Laboratory of Cell Transplantation, 150001 Harbin, Heilongjiang, China.
- Department of Clinical Pharmacy, Qiqihar Medical University, 161006 Qiqihar, Heilongjiang, China.
Förderung
- National Natural Science Foundation of China
- Heilongjiang Key R&D Program
- Fundamental Research Funds for the Provincial Universities in Heilongjiang Province (2025)
- Natural Science Foundation of Heilongjiang Province
- Innovation Fund of the First Affiliated Hospital of Harbin Medical University
- 2025 Central Government Fiscal Subsidy Fund for Medical Care Compliance and Capacity Enhancement (Traditional Chinese Medicine Undertakings and Inheritance and…
- 2025 Central Government Fiscal Subsidy Fund for Medical Care Compliance and Capacity Enhancement
Zitieren
APA
Guo, Z., Gao, Z., Zhao, Y., Ni, X., Zhang, W., Li, L., Ren, S., Li, Q., Guo, D., Yue, L., Liu, Y., Lin, L., Fan, S., & Hai, X. (2026). Administering Bifidobacterium pseudolongum With Arsenic Trioxide Attenuates Acute Promyelocytic Leukemia in Mice by Restoring Immune Microenvironment and Intestinal Homeostasis. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/fbl48584
Vancouver
Guo Z, Gao Z, Zhao Y, Ni X, Zhang W, Li L, et al. Administering Bifidobacterium pseudolongum With Arsenic Trioxide Attenuates Acute Promyelocytic Leukemia in Mice by Restoring Immune Microenvironment and Intestinal Homeostasis. Frontiers in Bioscience-Landmark. 2026. doi:10.31083/fbl48584
BibTeX
@article{Guo2026,
author = {Guo, Zhibo and Gao, Zengliang and Zhao, Yanqiu and Ni, Xiaoting and Zhang, Wenlei and Li, Longyu and Ren, Shiao and Li, Qi and Guo, Dan and Yue, Lijuan and Liu, Yutong and Lin, Liwang and Fan, Shengjin and Hai, Xin},
title = {Administering Bifidobacterium pseudolongum With Arsenic Trioxide Attenuates Acute Promyelocytic Leukemia in Mice by Restoring Immune Microenvironment and Intestinal Homeostasis},
journal = {Frontiers in Bioscience-Landmark},
year = {2026},
doi = {10.31083/fbl48584}
}
EUVIMED